Ctic
Ctic Chroma Therapeutics Ltd. Chroma candidate for cancer pipeline, tosedostat, for an initial payment of $ 5 million. Tosedostat is initially targeted to be developed for indications such as AML acute myeloid leukemia, myelodysplastic syndrome, MDS and multiple myeloma, Inc.
No comments:
Post a Comment